PEMOA33 | Serological responses to SARS-CoV2 vaccination in people with HIV: the SCAPE-HIV study | Poster exhibition | SARS-Cov2 vaccines |
PEMOA34 | Seroprevalence of cross-reactive anti-SARS-CoV-2 antibodies in pre-COVID-19 samples collected from Cameroonian women during pregnancy and at delivery | Poster exhibition | Immune responses to SARS-Cov2 |
PEMOA35 | Side-by-side comparison of SARS-CoV-2 neutralizing antibody responses after various COVID-19 vaccine regimens | Poster exhibition | SARS-Cov2 vaccines |
PEMOA36 | Immunogenicity of the BNT 162b2 mRNA vaccine against COVID-19 variants in people living with HIV on antiretroviral therapy in Malaysia | Poster exhibition | SARS-Cov2 vaccines |
PEMOA37 | Vaccine scheme, age and previous COVID-19 predict humoral response to SARS-CoV-2 vaccination in HIV-infected indivudals | Poster exhibition | SARS-Cov2 vaccines |
PEMOA38 | People living with HIV who are receiving suppressive antiretroviral therapy mount strong humoral responses to two and three doses of COVID-19 vaccine | Poster exhibition | SARS-Cov2 vaccines |
PEMOB27 | Persistent low-level viremia in the era of dolutegravir in four African countries | Poster exhibition | Adherence |
PEMOB28 | Safety outcomes among HIV-1 positive Zambian adults receiving Tenofovir Alafenamide combined with Dolutegravir: results from the VISEND clinical trial | Poster exhibition | Pregnancy (clinical management issues and pharmacokinetics) and contraception |
PEMOB29 | Selection of cabotegravir dosing regimens for HIV treatment and pre-exposure prophylaxis (PrEP) in adolescents by Leveraging adult data | Poster exhibition | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations |
PEMOB30 | Optimizing DTG uptake amongst children living with HIV in Ikom rural communities attending ART clinic at Comprehensive Health Center (CHC) Ikom, Cross River State | Poster exhibition | ARV management strategies in paediatric and adolescent populations |